Responsible advertising: We avoid unrealistic promises and focus on safe, medically guided care
Like any treatment, it may have side effects and is not suitable for everyone
Although these are rough estimates that rest upon assumptions about the relative rates and ability to detect DILI between different drugs (and between the US and Iceland), the EID provides informative rates for these rare events and likely explains why the risk of DILI may be missed in registration trials of new drugs which may enroll fewer than 1,000-3,000 patients
GLP-1 medications such as Wegovy, Ozempic, and Mounjaro have become widely known for their effects on appetite, blood sugar balance, and weight loss
In animal models of PD, GLP-1 receptor agonists reduced the activation of glia as well [150, 156, 157, 172]